Burning Rock Biotech Ltd ADR BNR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BNR is a good fit for your portfolio.
News
-
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
-
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
-
Burning Rock Reports First Quarter 2024 Financial Results
-
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
-
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
-
Burning Rock Publishes 2023 Annual Report on Form 20-F
-
Burning Rock Announces ADS Ratio Change
-
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / 88
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.25%
Company Profile
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- —
- Total Number of Employees
- 786
- Website
- https://www.brbiotech.com
Valuation
|
Metric
|
BNR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.73 |
Price/Sales | 1.01 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BNR
|
|---|---|
Quick Ratio | 2.86 |
Current Ratio | 3.29 |
Interest Coverage | — |
Quick Ratio
BNR
Profitability
|
Metric
|
BNR
|
|---|---|
Return on Assets (Normalized) | −49.66% |
Return on Equity (Normalized) | −67.64% |
Return on Invested Capital (Normalized) | −67.89% |
Return on Assets
BNR
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Mfmyrcrrjn | Gtjf | $218.4 Bil | |||
| Danaher Corp
DHR
| Xbgyncqzk | Xbqbf | $188.8 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Qbfmnhsxd | Qdltcp | $41.6 Bil | |||
| IQVIA Holdings Inc
IQV
| Pfvvzjkp | Jxtsdw | $38.8 Bil | |||
| Agilent Technologies Inc
A
| Zghbrssh | Wdvzp | $37.9 Bil | |||
| Mettler-Toledo International Inc
MTD
| Hcmsyjdsb | Sxzzsb | $31.1 Bil | |||
| Icon PLC
ICLR
| Rhcpkdd | Tdxqltc | $25.9 Bil | |||
| Waters Corp
WAT
| Yrrfswgpy | Xhtl | $17.5 Bil | |||
| Illumina Inc
ILMN
| Jnlszqcr | Pnqzk | $17.3 Bil | |||
| Labcorp Holdings Inc
LH
| Qfhcgsgss | Pzkjw | $16.8 Bil |